Janney Montgomery Scott LLC trimmed its position in shares of Allergan plc (NYSE:AGN) by 5.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,971 shares of the company’s stock after selling 2,390 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Allergan were worth $8,215,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in AGN. Prestige Wealth Management Group LLC purchased a new position in shares of Allergan in the 2nd quarter valued at about $25,000. Old North State Trust LLC lifted its stake in Allergan by 172.4% during the third quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the last quarter. HM Payson & Co. purchased a new stake in Allergan during the second quarter worth approximately $29,000. Reilly Financial Advisors LLC lifted its stake in Allergan by 129.3% during the third quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock worth $29,000 after purchasing an additional 97 shares during the last quarter. Finally, Fusion Family Wealth LLC increased its position in Allergan by 81.4% during the third quarter. Fusion Family Wealth LLC now owns 176 shares of the company’s stock worth $30,000 after buying an additional 79 shares during the period. Institutional investors own 82.27% of the company’s stock.
Several research analysts have commented on AGN shares. UBS Group lowered Allergan from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $189.00 to $203.00 in a research report on Tuesday, November 19th. ValuEngine lowered Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Co lowered Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 price target on the stock. in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, seventeen have issued a hold rating and three have assigned a buy rating to the company’s stock. Allergan presently has an average rating of “Hold” and a consensus price target of $176.63.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $4.25. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.25 earnings per share. Research analysts forecast that Allergan plc will post 16.88 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Friday, February 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.55%. Allergan’s dividend payout ratio is presently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: 52- Week Highs
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.